Thursday, January 27, 2011 11:57:09 AM
Date : 01/27/2011 @ 8:00AM
Source : GlobeNewswire Inc.
Stock : Discovery Laboratories, Inc. (DSCO)
http://ih.advfn.com/p.php?pid=nmona&article=46190024
Discovery Laboratories, Inc. (Nasdaq:DSCO) will host a conference call on Tuesday, February 1, 2011, at 10:00 AM EST. Management will provide an overview of Discovery Labs' efforts to gain U.S. Food and Drug Administration (FDA) marketing approval of Surfaxin® for the prevention of respiratory distress syndrome (RDS) in premature infants.
Discovery Labs believes that a key remaining issue necessary to potentially gain FDA marketing approval for Surfaxin is to satisfy the FDA as to the validation of the fetal rabbit biological activity test (BAT), an important quality control release and stability test for Surfaxin. On January 10, 2011, Discovery Labs issued a press release announcing that the FDA had recently provided detailed, written direction regarding certain components of Discovery Labs' comprehensive pre-clinical program, which is intended to potentially satisfy the FDA as to the validation of the BAT. As indicated in that press release, in the upcoming conference call, management will provide an overview of the program and review its progress.
Participants are encouraged to access this audio webcast through a live broadcast on the Company's website at www.discoverylabs.com. It is recommended that participants log onto the audio webcast at least 15 minutes prior to the call. The Internet broadcast will be available for up to 90 days after the call at the Company's website.
The call in number is 866-332-5218. The international call in number is 706-679-3237. A replay of the conference call will be available two hours after the call's completion and remain available through February 8, 2011. The replay number to hear the conference call is 800-642-1687 or 706-645-9291. The passcode is 40660551.
About Discovery Labs
Discovery Laboratories, Inc. is a biotechnology company developing KL4 surfactant therapies for respiratory diseases. Surfactants are produced naturally in the lungs and are essential for breathing. Discovery Labs' novel proprietary KL4 surfactant technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant and is being developed in liquid, aerosol and lyophilized formulations. In addition, Discovery Labs' proprietary capillary aerosolization technology produces a dense aerosol, with a defined particle size that is capable of potentially delivering aerosolized KL4 surfactant to the deep lung without the complications currently associated with liquid surfactant administration. Discovery Labs believes that its proprietary technology platform makes it possible, for the first time, to develop a significant pipeline of surfactant products to address a variety of respiratory diseases for which there frequently are few or no approved therapies. For more information, please visit our website at www.Discoverylabs.com.
CONTACT: John G. Cooper, President and Chief Financial Officer
215-488-9490
Recent WINT News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2024 09:28:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2024 09:27:47 PM
- Windtree Therapeutics Announces Closing of Financing Through a Private Placement of Series C Preferred Stock • GlobeNewswire Inc. • 07/22/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/22/2024 01:25:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/10/2024 08:53:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:59:51 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 05/09/2024 12:41:34 PM
- Windtree Therapeutics Regains Compliance with Nasdaq • GlobeNewswire Inc. • 05/07/2024 12:00:00 PM
- Windtree Therapeutics Announces Reverse Stock Split • GlobeNewswire Inc. • 04/18/2024 12:00:00 PM
- Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates • GlobeNewswire Inc. • 04/17/2024 12:00:00 PM
- Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing • GlobeNewswire Inc. • 04/08/2024 08:48:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 10:07:43 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/14/2024 10:23:27 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:30:23 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:15:54 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 09:40:42 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/01/2024 10:26:23 PM
- Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research • GlobeNewswire Inc. • 02/01/2024 01:00:00 PM
- Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives • InvestorsHub NewsWire • 01/31/2024 01:40:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 01:00:12 PM
- Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives • GlobeNewswire Inc. • 01/31/2024 01:00:00 PM
- Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company • InvestorsHub NewsWire • 01/25/2024 02:04:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 01:34:03 PM
- Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company • GlobeNewswire Inc. • 01/25/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 09:45:14 PM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM